PMID- 22476807
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20211021
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 31
IP  - 7
DP  - 2012 Jul
TI  - A randomized, single-blind comparison of the efficacy and tolerability of 
      hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the 
      knee.
PG  - 1079-86
LID - 10.1007/s10067-012-1979-3 [doi]
AB  - The aim of this study was to prospectively evaluate the efficacy and tolerability 
      of hyaluronic acid (HA) and meloxicam for the treatment of knee pain due to 
      Kashin-Beck disease (KBD). A total of 162 patients with KBD-based knee pain were 
      randomly assigned to treatment with a 3-week course of HA (n = 80) and a 12-week 
      course of meloxicam (n = 82). Clinical assessments for each patient were made at 
      0 (baseline), 1, 2, 4, 8, and 12 weeks. The primary efficacy measure was visual 
      analog scale (VAS) pain score. Second efficacy measures comprised the Western 
      Ontario and McMaster Universities (WOMAC) A (pain), B (stiffness), and C 
      (function) scores as well as patients' and physicians' global assessments. 
      Tolerability was evaluated based on adverse events (AEs) and physician reporting. 
      The VAS rapidly decreased in both groups over 12 weeks. The VAS improvement 
      observed in HA group was lower at week 1 (p = 0.001) but better at weeks 8 and 12 
      (p < 0.001) than the meloxicam group, which were supported by the secondary 
      variables of WOMAC A (p = 0.001) and WOMAC C (p < 0.001) scores and the global 
      assessments of the patients and their physicians (p = 0.020 and 0.003, 
      respectively). No serious AEs were reported, and the overall incidence of AEs 
      among patients treated with meloxicam was higher than in patients treated with HA 
      (p = 0.012). This study suggests that intra-articular injection of HA and 
      administration of oral meloxicam should be efficacious and well tolerated in the 
      treatment of knee pain due to KBD; the onset of action of meloxicam was faster 
      than that of HA, whereas HA therapy resulted in a more prolonged increasing 
      improvement of symptoms than meloxicam. In addition, HA treatment was likely 
      superior to meloxicam with respect to tolerability. Other randomized double-blind 
      studies are needed to confirm the findings of our open-label study.
FAU - Tang, Xin
AU  - Tang X
AD  - Department of Orthopaedic surgery, West China Hospital of Sichuan University, No. 
      37, Guoxue Alley, Chengdu 610041, People's Republic of China.
FAU - Pei, Fu-Xing
AU  - Pei FX
FAU - Zhou, Zong-Ke
AU  - Zhou ZK
FAU - Liu, Gang
AU  - Liu G
FAU - Shen, Bin
AU  - Shen B
FAU - Kang, Peng-De
AU  - Kang PD
FAU - Li, Jian
AU  - Li J
FAU - Zhao, Xiao-Dan
AU  - Zhao XD
FAU - Li, Qi
AU  - Li Q
FAU - Li, Yong
AU  - Li Y
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120403
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - 0 (Viscosupplements)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/administration & dosage/adverse effects/*therapeutic use
MH  - Injections, Intra-Articular
MH  - Kashin-Beck Disease/*drug therapy/physiopathology
MH  - Knee Joint/*physiopathology
MH  - Male
MH  - Meloxicam
MH  - Middle Aged
MH  - Pain/*drug therapy/physiopathology
MH  - Pain Measurement
MH  - Single-Blind Method
MH  - Thiazines/administration & dosage/adverse effects/*therapeutic use
MH  - Thiazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Viscosupplements/adverse effects/*therapeutic use
EDAT- 2012/04/06 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/04/06 06:00
PHST- 2012/01/10 00:00 [received]
PHST- 2012/03/20 00:00 [accepted]
PHST- 2012/03/06 00:00 [revised]
PHST- 2012/04/06 06:00 [entrez]
PHST- 2012/04/06 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1007/s10067-012-1979-3 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2012 Jul;31(7):1079-86. doi: 10.1007/s10067-012-1979-3. Epub 2012 
      Apr 3.